GALLEX 6: Study to Evaluate the Safety and Tolerability of Tesaglitazar in Patients With Type 2 Diabetes Mellitus
Status:
Terminated
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
This is a parallel-group, multi-center, long-term extension study from the GALLANT 6 study to
monitor the safety and tolerability of oral tesaglitazar compared with pioglitazone in
patients with type 2 diabetes for up to 104 weeks of treatment. The total duration, including
treatment and follow-up, is 107 weeks.